Analysts Are Bullish on These Healthcare Stocks: JAZZ, ONCE

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Jazz Pharmaceuticals (NASDAQ: JAZZ) and Spark Therapeutics (NASDAQ: ONCE) with bullish sentiments.

Jazz Pharmaceuticals (NASDAQ: JAZZ)

BMO Capital analyst Gary Nachman maintained a Buy rating on Jazz Pharmaceuticals (NASDAQ: JAZZ) today and set a price target of $201. The company’s shares opened today at $152.

According to TipRanks.com, Nachman is a 4-star analyst with an average return of 11.9% and a 55.2% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Pacira Pharmaceuticals, and scPharmaceuticals Inc.

Currently, the analyst consensus on Jazz Pharmaceuticals is Strong Buy and the average price target is $189.22, representing a 24.5% upside.

In a report issued on May 1, B.Riley FBR also maintained a Buy rating on the stock with a $206 price target.

See today’s analyst top recommended stocks >>

Spark Therapeutics (NASDAQ: ONCE)

In a report released today, Matthew Luchini from BMO Capital maintained a Buy rating on Spark Therapeutics (NASDAQ: ONCE), with a price target of $78. The company’s shares opened today at $70.48.

According to TipRanks.com, Luchini is a 1-star analyst with an average return of -1.1% and a 40.0% success rate. Luchini covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Bluebird Bio, and Regeneron.

Currently, the analyst consensus on Spark Therapeutics is Moderate Buy and the average price target is $80.36, representing a 14.0% upside.

In a report issued on April 30, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $103 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.